Expert Consultations: Real-World Answers

Pharmacologic Management of BPD: Recent Developments-Interview

Published on January 1, 2023 Certification expiration date: January 1, 2029

Guest

Radwa Hanafy

To unlock this audio you need to become a Silver, Gold, Silver extended, Gold extended, Gold – fr, Gold extended – fr, Silver – fr or Silver extended – fr Member.

Check Our CME Program

Downloads for Offline Access

Download Audio File (MP3)

Interview Highlights

Psychotherapy continues to be the main treatment modality for patients with borderline personality disorder.
Psychotropic medications may be used to manage comorbid disorders, such as depression or anxiety, as well as targeted symptoms, such as impulsivity, aggressiveness, and cognitive–perceptual disturbances.

Text Version

This edition of Psychopharmacology Institute’s Expert Consultations features Paul Links, M.D., professor of psychiatry at McMaster University in Hamilton, Ontario, Canada. In this interview, we will discuss recent developments in the pharmacologic management of borderline personality disorder.

Radwa Hanafy, M.D.: Dr. Links, it's a great pleasure having you with us today. Before we dive into the interview, I would like to talk about the concept of using medication for the treatment of borderline personality disorder (BPD). Several guidelines agree

Unlock this Expert Consultation and earn 0.50 CMEs
Become a Silver, Gold, Silver extended, Gold extended, Gold – fr, Gold extended – fr, Silver – fr or Silver extended – fr Member.

Get Instant Access

Already have an account? Sign in

Learning Objectives:

After completing this activity, the learner will be able to:

Recognize the importance of engaging patients with borderline personality disorder in treatment planning and selection.
Discuss practical considerations in selecting and initiating psychotropic medications for patients with borderline personality disorder.

Original Release Date: January 1, 2023

Review and Re-release Date: January 1, 2026

Expiration Date: January 1, 2029

Expert: Paul Links, M.D.

Medical Editors: Radwa Hanafy, M.D., Melissa Mariano, M.D.

Relevant Financial Disclosures:

Paul S. Links declares the following interests:

– American Psychiatric Association Publishing: book royalties

All of the relevant financial relationships listed above have been mitigated by Medical Academy and the Psychopharmacology Institute.

Contact Information: For questions regarding the content or access to this activity, contact us at support@ml-prod.psychopharmacologyinstitute.com

Instructions for Participation and Credit:

Participants must complete the activity online during the valid credit period that is noted above.

Follow these steps to earn CME credit:

View the required educational content provided on this course page.
Answer the quiz for promoting retention of knowledge.
Complete the Post Activity Evaluation for providing the necessary feedback for continuing accreditation purposes and for the development of future activities. NOTE: Completing the Post Activity Evaluation after the quiz is required to receive the earned credit.
Download your certificate.

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of Medical Academy LLC and the Psychopharmacology Institute. Medical Academy is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation Statement

Medical Academy designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Paul Links, M.D.